The Nanoparticle Formulation Market Size is valued at 5.08 billion in 2022 and is predicted to reach 10.76 billion by the year 2031 at an 8.8% CAGR during the forecast period for 2023-2031.
Nanoparticles are particles in the nanometer scale from 1 to 100 nm in diameter. These particles have proven helpful in many areas, including biomedicine, commonly for implants & drug delivery. Drug delivery with nanoparticles is an exciting field in which therapeutic compounds use nanoparticles as carriers to improve absorption, solubility, stability and decrease toxicity of the body.
Natural ingredients are back in fashion and useful because of their low toxicity and fewer side effects. However, natural compounds generally have low bioavailability and solubility, meaning the digestive system cannot readily absorb them. A feasible solution to these hitches is the usage of nanoparticles as drug delivery systems to act as delivery vehicles for therapeutics. Nanoparticles can provide many advantages for drug delivery, such as site-specific delivery and increased bioavailability. Additionally, nanoparticles aid in treating various disease conditions, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders.
Due to the challenges related to process development, consistency of the constructs & reproducibility, biopharma companies started to opt for contract manufacturing services to save time and reduce the complexity of nanoparticle formulations.
Many research firms are seeking novel nanoparticle delivery technologies and focusing on more patient-centricity in drug development.
Competitive Landscape:
Some of the Key Players in the Nanoparticle Formulation Market:
- Ascension Sciences
- DIANT Pharma
- ExonanoRNA
- Nanoform
- NanoVation Therapeutics
- NanoVelos
- NTT Biopharma
- Organoid-X BioTech
- Vaxinano
- Other Prominent Players
Market Segmentation:
The Nanoparticle Formulation Market is categorized into type of nanoparticle formulated, type of organic nanoparticle formulated, type of inorganic nanoparticle formulated, and scale of operation. The type of nanoparticle formulated segment comprises organic nanoparticles, inorganic nanoparticles, and carbon-based nanoparticles. By type of organic nanoparticle formulated, the market is divided into polymeric nanoparticles, lipid nanoparticles, viral nanoparticles, protein-based nanoparticles, and other organic nanoparticles.
The type of inorganic nanoparticle formulated segment consists of metal nanoparticles, quantum dots, silica nanoparticles, magnetic nanoparticles, and other inorganic nanoparticles. Based on the scale of operation, the market is segmented into preclinical, clinical, and commercial.
The Lipid Nanoparticle Formulation Is Expected To Drive The Nanoparticle Formulation Market
Due to several advantages of lipid nanoparticles in therapeutics, pharma companies are collaborating with industries specializing in lipid nanoparticle formulation to expand their capabilities and improve product quality. In September 2022, NeoVac and Aragen Life Sciences Private Limited announced an agreement to create a lipid product that will enable the development of lipid nanoparticles (LNP) for use in producing RNA vaccines for various diseases. In 2021, WACKER collaborated with CordenPharma. Both companies reported that they intend to jointly develop novel methods for manufacturing Lipid Nanoparticles (LNPs) to meet the growing market demand.
In Terms Of The Scale Of Operation, The Clinical Segment Dominates The Market
The clinical category is expected to retain a significant share of the nanoparticle formulation market over the forecast period. Many ongoing clinical studies on drug therapies and vaccines for treating various diseases, including cancer, cardiovascular diseases (CVDs), and infectious diseases, are expanding the clinical segment of the market.
Regionally, North America Dominated The Nanoparticle Formulation Market In 2022
Factors such as the surging demand for targeted therapies, innovations in nanoparticle delivery systems, and increasing research efforts in drug development technologies are responsible for the blooming of the nanoparticle formulation market in North America, followed by Europe. At the same time, the Asia Pacific regional market is predicted to witness steady growth in the next few years. Increasing inventions, the introduction of nanoparticle delivery systems, and growing chronic diseases will likely drive the nanoparticle formulation market in this region.
Nanoparticle Formulation Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 5.08 Bn |
|
Revenue Forecast In 2031 |
USD 10.76 Bn |
|
Growth Rate CAGR |
CAGR of 8.8 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Nanoparticle Formulated, By Type of Organic Nanoparticle Formulated, By Type of Inorganic Nanoparticle Formulated, By Scale of Operation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Ascension Sciences, DIANT Pharma, ExonanoRNA, Nanoform, NanoVation Therapeutics, NanoVelos, NTT Biopharma, Organoid-X BioTech, Vaxinano, and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
